MECC Masters in Thoracic Oncology Summit MaTOS 2023

Include: 52 videos, size: 4.51 GB

Topics:

ALK in Front Line Therapy Second or Third Generation TKI Inhibitors What Can Help Us to Choose the Best Therapeutic Agent.mp4
Anti-CEACAM and ROR ADCs.mp4
Best Approaches for First Line EGFRm NSCLC.mp4
Best Surgical Approaches for Stage III NSCLC.mp4
Biomarkers for Perioperative Immunotherapy.mp4
Brain Radiotherapy in Small Cell Lung Cancer When.mp4
Cellular Therapies in NSCLC Is it feasible.mp4
ctDNA Analyses in Early Detection Methylation, Proteomics and Other Efforts for Early Lung Cancer Detection.mp4
Deciphering the Mechanism of Resistance to First Generation KRAS Inhibitors.mp4
Developing New Anti-CTL4s for NSCLC Is There Any Role.mp4
Early Stage Resectable Lung Cancer Adjuvant Immunotherapy.mp4
Exon 20 and Uncommon EGFR Sensitive Mutations.mp4
Frontline What are We Adding to Checkpoint Inhibitors and Chemotherapy.mp4
Future Challenges for lmmunotherapy in the Fight Against NSCLC.mp4
Health Care Disparities in Lung Cancer Genomic Profiling Has Precision Oncology Widened the Gap.mp4
HER-3 as a New Target in NSCLC.mp4
HER2 Tx in Advanced NSCLC From TKls to ADCs.mp4
How to Rescue Patients from Osimertinib Resistance.mp4
How to Start a Lung Cancer Screening Program.mp4
Improving Targeted Therapies for Patients with Lung Cancers Where are the gaps and ways to fill them.mp4
KRAS mutant NSCLC What is the Standard of Care Now.mp4
Lack of Equity in Clinical Outcomes in Blacks and Hispanics with NSCLC.mp4
Limited Stage SCLC 2023.mp4
Management of LA-NSCLC in Pts with PD-L1 – 1% or Oncogenic Drivers.mp4
Mechanisms of Resistance to ALK Inhibitors.mp4
Minimal Residual Disease as Detected by Liquid Biopsy Where are We Going.mp4
MRD to Decide Perioperative Management in the Era of Immuno-Oncology.mp4
Neoadjuvant Immunotherapy Position.mp4
Novel Therapies for Thymic Malignancies.mp4
NRG1 as a Target in NSCLC.mp4
Optimal Management of Extensive SCLC (1st and 2nd Line).mp4
Overcoming T-Cell Exhaustion.mp4
Pan-KRAS Inhibitors Where are We Going.mp4
PARP Inhibitors in SCLC.mp4
Predictive Biomarkers in Small Cell Lung Carcinoma.mp4
Radiation Induced Immune Responses in NSCLC.mp4
RET and NTRK The Good, The Bad, The Ugly…. and What’s Coming Up.mp4
Role of Interleukins to Improve Efficacy of Immunotherapy.mp4
Role of Radiotherapy in TIME Good Bad Don’t know.mp4
ROS1 and BRAf Inhibitors New Developments.mp4
Stage III Non-Surgical NSCLC Optimal Radiation Therapy Treatment Approach.mp4
Strategies to Target Minimal Residual Disease in Lung Cancer.mp4
Surgery for Malignant Pleural Mesothelioma.mp4
Systemic Therapies for Mesothelioma.mp4
The Importance of TIME in Cancer Treatment How to Target It.mp4
The New Role of Microbiome in Lung Cancer Immunotherapy.mp4
The Role of Co-Mutations in Immunotherapy Response in NSCLC.mp4
The Role of SHP-2 Inhibitors Alone or in Combination.mp4
TROP-2 and AXL as Targets in NSCLC.mp4
Updates in Bispecific Antibodies in NSCLC.mp4
What Comes After Immunotherapy Failure in Terms of More Immunomodulation.mp4
What’s After PACIFIC Can We Raise the Bar.mp4